Physician profile
Kinim I Smith
NPI 1275646473
$5,711.82
in general payments reported to CMS, 2019-2025
25 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $295 · 2021: $440 · 2022: $968 · 2023: $551 · 2024: $1,116 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.62 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,055.90 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $901.46 | 2022-2025 | Humira, Rinvoq |
| Janssen Biotech, INC. | $496.69 | 2019-2025 | Tremfya |
| Amgen INC. | $479.00 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Astrazeneca Pharmaceuticals LP | $394.05 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $322.89 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $290.57 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $249.06 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $248.07 | 2019-2021 | |
| Genentech USA, INC. | $218.77 | 2019-2025 | Actemra |
| Lilly USA, LLC | $175.23 | 2019-2024 | Taltz |
| Kyowa Kirin, INC. | $142.49 | 2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $127.66 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.16 | 2022-2024 | Ofev |
| Horizon Therapeutics Plc | $80.57 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.73 | 2022-2025 | |
| Sandoz INC. | $70.32 | 2023-2024 | Hyrimoz |
| Organon LLC | $63.77 | 2025 | Hadlima |
| Mallinckrodt Hospital Products INC. | $60.44 | 2022 | |
| Mallinckrodt Enterprises LLC | $41.66 | 2019 | |
| Collegium Pharmaceutical, INC. | $39.04 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.11 | 2025 | |
| Aurinia Pharma U.S., INC. | $20.70 | 2021 | |
| Fidia Pharma USA INC. | $19.12 | 2019 | |
| Shionogi INC | $16.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinim Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.